• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024

    6/10/24 8:00:00 AM ET
    $AIM
    $AREC
    $CNSP
    $GRI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Coal Mining
    Energy
    Get the next $AIM alert in real time by email

    - Live video webcast presentations with Q&A

    - Preliminary schedule of participating companies now available at www.virtualinvestorco.com

    FRENCHTOWN, NJ / ACCESSWIRE / June 10, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor Pitch Conference on June 17-18, 2024.

    For the event, participating companies will provide their "elevator pitch" and outline upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as time allows.

    The current schedule of participating companies is as follows:

    Monday, June 17

    • 10:00 AM ET: Adolore BioTherapeutics, Inc. (Private) - Webcast
    • 11:00 AM ET: CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - Webcast
    • 12:00 PM ET: Palisade Bio, Inc. (NASDAQ:PALI) - Webcast
    • 1:00 PM ET: AIM ImmunoTech Inc. (NYSE:AIM) - Webcast
    • 4:00 PM ET: enVVeno Medical Corporation (NASDAQ:NVNO) - Webcast

    Tuesday, June 18

    • 10:00 AM ET: Royalty Management Holding Corporation (NASDAQ:RMCO) - Webcast
    • 11:00 AM ET: GRI Bio, Inc. (NASDAQ:GRI) - Webcast
    • 12:00 PM ET: Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Webcast
    • 1:00 PM ET: American Resources Corporation (NASDAQ:AREC) - Webcast
    • 3:00 PM ET: Moleculin Biotech, Inc. (NASDAQ:MBRX) - Webcast

    All investors and interested parties can access the event schedule and individual company webcast details at www.virtualinvestorco.com. Webcast replays will be made available shortly after the conclusion of the live event and will be accessible for 90 days.

    To access all Virtual Investor events, visit www.virtualinvestorco.com.

    About JTC Team

    JTC is a fully integrated investor relations firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on Twitter and LinkedIn.

    Contact:

    Jenene Thomas
    JTC Team, LLC
    T: +1 (833) 475-8247
    jtc@jtcir.com

    SOURCE: JTC Team, LLC



    View the original press release on accesswire.com

    Get the next $AIM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIM
    $AREC
    $CNSP
    $GRI

    CompanyDatePrice TargetRatingAnalyst
    Outlook Therapeutics Inc.
    $OTLK
    5/18/2026Buy → Neutral
    BTIG Research
    Palisade Bio Inc.
    $PALI
    4/9/2026$7.00Outperform
    Wolfe Research
    Palisade Bio Inc.
    $PALI
    3/26/2026$7.00Buy
    H.C. Wainwright
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    American Resources Corporation
    $AREC
    11/26/2025$7.00Buy
    Maxim Group
    American Resources Corporation
    $AREC
    10/20/2025Outperform
    William Blair
    More analyst ratings

    $AIM
    $AREC
    $CNSP
    $GRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Outlook Therapeutics downgraded by BTIG Research

    BTIG Research downgraded Outlook Therapeutics from Buy to Neutral

    5/18/26 8:32:11 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Palisade Bio with a new price target

    Wolfe Research initiated coverage of Palisade Bio with a rating of Outperform and set a new price target of $7.00

    4/9/26 8:43:44 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Palisade Bio with a new price target

    H.C. Wainwright initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    3/26/26 8:49:56 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIM ImmunoTech Releases Virtual Investor 'What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparedness

    Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen's previously published antiviral research Discussion highlights Ampligen's immune-modulating mechanism, prior Biosafety Level 4 findings and potential applicability across emerging viral threats New Ebola-focused corporate presentation highlighting Ampligen's antiviral research and preparedness potential is now accessible here Access the ‘What This Means' video segment here OCALA, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the release of a Virtual Investor "What This Means" video segment featuring AIM Chie

    6/4/26 8:55:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor "What This Means" Segment

    - Access the segment here HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr. Klemp discussed the Company's recent news announcing that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R/R AML). Mr. Klemp gave insight into how this milestone triggers the final phase of preparation

    6/4/26 8:31:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

    OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a significant milestone in its pancreatic cancer development program, with enrollment of the final subject, barring disqualifying pre-treatment circumstances. The final planned subject is scheduled for treatment in mid-June, surpassing the Company's original enrollment target of July 2026 in the Phase 2 clinical trial of AIM's drug Ampligen® (rintatolimod) combined with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the "DURIPANC" stud

    6/1/26 8:58:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Haddadin Yezan Munther bought $24,145 worth of shares (29,000 units at $0.83), increasing direct ownership by 78% to 66,167 units (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    6/3/26 6:03:16 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sukhtian Ghiath M. bought $5,000,000 worth of shares (8,539,709 units at $0.59) (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    6/1/26 9:30:12 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sukhtian Faisal Ghiath bought $50,006 worth of shares (122,174 units at $0.41), increasing direct ownership by 3,593% to 125,574 units (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    5/27/26 3:29:11 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AIM
    $AREC
    $CNSP
    $GRI
    SEC Filings

    View All

    Director Haddadin Yezan Munther bought $24,145 worth of shares (29,000 units at $0.83), increasing direct ownership by 78% to 66,167 units (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    6/3/26 6:03:16 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sukhtian Ghiath M. bought $5,000,000 worth of shares (8,539,709 units at $0.59) (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    6/1/26 9:30:12 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sukhtian Faisal Ghiath bought $50,006 worth of shares (122,174 units at $0.41), increasing direct ownership by 3,593% to 125,574 units (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    5/27/26 3:29:11 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    American Resources Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - American Resources Corp (0001590715) (Filer)

    6/4/26 10:03:44 AM ET
    $AREC
    Coal Mining
    Energy

    AIM ImmunoTech Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - AIM ImmunoTech Inc. (0000946644) (Filer)

    6/4/26 9:00:38 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Outlook Therapeutics Inc.

    DEFA14A - Outlook Therapeutics, Inc. (0001649989) (Filer)

    6/1/26 5:00:43 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Financials

    Live finance-specific insights

    View All

    Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

    Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026 following 45 subject enrollment milestone achieved in MIRACLE trial Enrollment in MIRACLE trial continues to advance on pace with 90th subject expected in Q3 2026 HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update. "With enrollment now surpassing the first interim analysis threshold in the MIRACLE trial, we are just weeks away from beginning wh

    5/15/26 8:30:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease

    PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat populationPhase 1b data demonstrate endoscopic improvement, with a 47.5% reduction in SES-CD score and 40% of patients achieving endoscopic response and 40% of patients achieving endoscopic remissionPharmacokinetic and pharmacodynamic data from ileal tissue and plasma support once-daily oral dosing for Crohn's disease showing IC90 coverage, with correlation to accepted inflammatory biomarkers Data support expansion into broader luminal CD, an indication that has regulatory clarity, more than doubles the total addressable patient population, and has no a

    3/30/26 4:01:00 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

    Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today reported financial results for the year ended December 31, 2025 and provided a clinical update highlighting rapid progress toward a major upcoming milestone in its pivotal MIRACLE trial of Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML). "With the MIRACLE trial rapidly progressing and the first MIRACLE i

    3/19/26 8:36:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

    SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

    11/14/24 5:12:06 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

    SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    11/14/24 4:55:26 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

    ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. "We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. "Laura's two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value

    1/6/26 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care